Cargando…

Palliative care and end of life management in patients with idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Micco, Assunta, Carpentieri, Emanuela, Di Sorbo, Antonio, Chetta, Alfredo, Del Donno, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994447/
https://www.ncbi.nlm.nih.gov/pubmed/36909932
http://dx.doi.org/10.4081/mrm.2023.896
_version_ 1784902634823483392
author Micco, Assunta
Carpentieri, Emanuela
Di Sorbo, Antonio
Chetta, Alfredo
Del Donno, Mario
author_facet Micco, Assunta
Carpentieri, Emanuela
Di Sorbo, Antonio
Chetta, Alfredo
Del Donno, Mario
author_sort Micco, Assunta
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall survival of 5 years in approximately 20% of patients without treatment. The combination of a poor prognosis, uncertainty about the disease's progression, and the severity of symptoms has a significant impact on the quality of life of patients and their families. New antifibrotic drugs have been shown to slow disease progression, but their impact on health-related quality of life (HRQoL) has to be proven yet. To date, studies have shown that palliative care can improve symptom management, HRQoL, and end-of-life care (EoL) in patients with IPF, reducing critical events, hospitalization, and health costs. As a result, it is essential for proper health planning and patient management to establish palliative care early and in conjunction with other therapies, beginning with the initial diagnosis of the disease.
format Online
Article
Text
id pubmed-9994447
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-99944472023-03-09 Palliative care and end of life management in patients with idiopathic pulmonary fibrosis Micco, Assunta Carpentieri, Emanuela Di Sorbo, Antonio Chetta, Alfredo Del Donno, Mario Multidiscip Respir Med Review Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall survival of 5 years in approximately 20% of patients without treatment. The combination of a poor prognosis, uncertainty about the disease's progression, and the severity of symptoms has a significant impact on the quality of life of patients and their families. New antifibrotic drugs have been shown to slow disease progression, but their impact on health-related quality of life (HRQoL) has to be proven yet. To date, studies have shown that palliative care can improve symptom management, HRQoL, and end-of-life care (EoL) in patients with IPF, reducing critical events, hospitalization, and health costs. As a result, it is essential for proper health planning and patient management to establish palliative care early and in conjunction with other therapies, beginning with the initial diagnosis of the disease. PAGEPress Publications, Pavia, Italy 2023-02-21 /pmc/articles/PMC9994447/ /pubmed/36909932 http://dx.doi.org/10.4081/mrm.2023.896 Text en ©Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Micco, Assunta
Carpentieri, Emanuela
Di Sorbo, Antonio
Chetta, Alfredo
Del Donno, Mario
Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
title Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
title_full Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
title_fullStr Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
title_full_unstemmed Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
title_short Palliative care and end of life management in patients with idiopathic pulmonary fibrosis
title_sort palliative care and end of life management in patients with idiopathic pulmonary fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994447/
https://www.ncbi.nlm.nih.gov/pubmed/36909932
http://dx.doi.org/10.4081/mrm.2023.896
work_keys_str_mv AT miccoassunta palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis
AT carpentieriemanuela palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis
AT disorboantonio palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis
AT chettaalfredo palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis
AT deldonnomario palliativecareandendoflifemanagementinpatientswithidiopathicpulmonaryfibrosis